Incretin-related drugs, including glucagon-like peptide-1 (GLP-1) receptor analogs and dipeptidyl peptidase-4 inhibitors, were proposed as treatment options to address these issues in patients with DM (4, 5, 6). The gene discussed is GCG; the disease is diabetes mellitus.